文献速递泌尿生殖MR

局限性前列腺癌HIFU治疗后mpMRI监测中TARGET与PI-FAB评分的对比分析

Comparative analysis of TARGET and PI-FAB scores in mpMRI surveillance after HIFU therapy for localized prostate cancer.
PubMed 文献 · Eur J Radiol · 2025-03-04

这项经IRB批准的回顾性单中心研究纳入83例局限性前列腺癌HIFU治疗后随访mpMRI并穿刺活检的患者,比较TARGET与PI-FAB评分的诊断效能。两评分读者间一致性为中等至几乎完全一致,总体特异度与阴性预测值较高,敏感度与阳性预测值相对较低,两评分间诊断效能无统计学显著差异。作者认为两评分效能相当,尤其有助于排除靶区内临床显著复发,但HIFU后局部肿瘤复发的检出仍具挑战,需进一步改进和优化评分。

要点

  • TARGET与PI-FAB评分读者间一致性为中等至几乎完全一致(AC1=0.78-0.83/0.70-0.96)。
  • 两评分总体特异度和阴性预测值较高,敏感度和阳性预测值相对较低。
  • 两评分间及两位读者间诊断效能均无统计学显著差异(p>0.05)。

核心结论

  • TARGET与PI-FAB评分诊断效能相当,尤其有助于排除HIFU后靶区内临床显著前列腺癌复发,可能作为HIFU治疗后综合监测策略中有价值的无创工具。
  • HIFU治疗后局部肿瘤复发的检出仍具挑战,需进一步改进和优化评分。

研究设计与样本

  • 经IRB批准的回顾性单中心研究,纳入83例局限性前列腺癌HIFU治疗后于6、12、36个月行随访mpMRI并后续穿刺活检的患者(2014年5月至2021年10月)。
  • 两位放射科医师独立评估TARGET与PI-FAB评分,采用Gwet的AC1评估读者间一致性。
  • 以组织病理学活检结果为参考标准,分析两评分的诊断效能。

诊断标准与关键数值

  • 读者间一致性:TARGET评分AC1=0.78-0.83,PI-FAB评分AC1=0.70-0.96(不同随访时间点的范围)。
  • 总体特异度:TARGET评分读者1为92%、读者2为89%;PI-FAB评分读者1为90%、读者2为90%。
  • 总体阴性预测值:TARGET评分读者1为87%、读者2为81%;PI-FAB评分读者1为84%、读者2为80%。
  • 总体敏感度:TARGET评分读者1为55%、读者2为35%;PI-FAB评分读者1为45%、读者2为30%。
  • 总体阳性预测值:TARGET评分读者1为69%、读者2为50%;PI-FAB评分读者1为60%、读者2为50%。

临床应用与阅片要点

  • 两评分可能作为HIFU治疗后综合监测策略的一部分,尤其用于排除靶区内临床显著前列腺癌复发。
  • HIFU治疗后局部肿瘤复发的检出仍具挑战,评分的进一步改进和优化仍有必要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To validate the TARGET score for multiparametric MRI (mpMRI) following high-intensity focused ultrasound (HIFU) therapy and to compare its diagnostic performance to the PI-FAB score.

METHODS: This IRB-approved retrospective, single-center study included 83 patients who underwent follow-up mpMRIs and subsequent prostate biopsies at 6, 12, and 36 months after HIFU therapy for localized prostate cancer (05/2014-10/2021). Two radiologists independently assessed TARGET and PI-FAB scores. Inter-reader agreement was assessed using Gwet's AC1. Diagnostic performance was analyzed for both scores using histopathologic biopsy results as the reference standard.

RESULTS: Follow-up mpMRIs of 83 patients were evaluated. Inter-reader agreement was substantial to almost perfect for both scores (AC1 = 0.78-0.83/ 0.70-0.96; TARGET/PI-FAB, ranges across the different follow-up intervals). Both the TARGET and PI-FAB score demonstrated high overall specificities (TARGET: 92 %/89 %; PI-FAB: 90 %/90 % for Reader 1/Reader 2) and NPVs (87 %/81 %; 84 %/80 %). Overall sensitivities (55 %/35 %; 45 %/30 %) and PPVs (69 %/50 %; 60 %/50 %) for both scores were comparatively lower. No statistically significant differences in diagnostic performance were identified between the two scores and readers (p > 0.05).

CONCLUSION: Both scores demonstrated comparable diagnostic performance particularly in excluding in-field clinically significant prostate cancer recurrence post-HIFU and thus may be valuable, non-invasive tools as part of comprehensive monitoring strategies after HIFU treatment. However, challenges in detecting local tumor recurrence after HIFU therapy persist and require further refinement and optimization of the scores.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Pausch AM, Elsner C, Rupp NJ, et al. Comparative analysis of TARGET and PI-FAB scores in mpMRI surveillance after HIFU therapy for localized prostate cancer. Eur J Radiol. 2025. PMID: 40058174. doi:10.1016/j.ejrad.2025.112028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。